Real-World Treatment Patterns and Patient Reported Outcome in COPD (REMIND)

AstraZeneca

Status: Completed

Conditions: COPD

Study type: Observational

Funder types: Industry

Identifiers

NCT05903989

D5980R00080

Details and patient eligibility

About

This retrospective observational study aims to report distribution of the proportion of symptomatic Chronic obstructive pulmonary disease (COPD) patients classified by the COPD Assessment Test (CAT) managed with single or dual inhaler treatment using the data at cohort entry in the COPD cohort study, and treatment change and longitudinal CAT score by each inhaler treatment will also be evaluated using the data during the follow-up period.

Enrollment: 708 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients taken with any of following inhaler treatments; LAMA, LAMA+LABA(both single and dual inhaler) or ICS+LABA(both single and dual inhaler) at cohort entry

Exclusion criteria

• Patients enrolled at the sites participated in the COPD cohort study where not agreed on secondary use of data for this study

Trial design

708 participants in 3 patient groups

LAMA

LAMA plus LABA

ICS plus LABA